SCHEMBL4418327

SCHEMBL4418327

CC(C)(C)OC(=O)N1CCN2C(=O)c3c(cccc3-c3ccc(F)cc3)OCC2C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.40
HDAC6 Q9UBN7 2/20 0.38
HDAC1 Q13547 2/20 0.38
HDAC2 Q92769 2/20 0.38
BTK Q06187 1/20 0.37
SCN9A Q15858 1/20 0.37
JAK2 O60674 1/20 0.37
JAK3 P52333 1/20 0.37
PTK2 Q05397 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
SMARCA2 P51531 1/20 0.36
SMARCA4 P51532 1/20 0.36
PBRM1 Q86U86 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SETD7 Q8WTS6 1/20 0.36
TP53 P04637 1/20 0.35
MMP13 P45452 1/20 0.35
EGFR P00533 1/20 0.35
SRC P12931 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4411286 0.92 USP30 (0.44) USP30HDAC6HDAC8SMARCA2SMARCA4
SCHEMBL4415912 0.91 USP30 (0.41) USP30HDAC6SCN9AHDAC8SMARCA2
SCHEMBL4410015 0.89 SCN9A (0.42) USP30HDAC6BTKSCN9AHDAC8
SCHEMBL4413014 0.87 GPR119 (0.40) USP30HDAC6SCN9AHDAC8SMARCA2
SCHEMBL4410012 0.84 USP30 (0.42) USP30SCN9ATP53
SCHEMBL4415998 0.83 USP30 (0.42) USP30HDAC6SCN9AHDAC8TP53
SCHEMBL4408961 0.83 USP30 (0.43) USP30HDAC6SCN9AHDAC8SMARCA2
SCHEMBL4412319 0.83 USP30 (0.43) USP30SCN9AMEN1KMT2ATP53
SCHEMBL4408213 0.83 USP30 (0.43) USP30HDAC6SCN9AHDAC8SMARCA2
SCHEMBL4411273 0.81 USP30 (0.44) USP30SCN9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318412-A1 Tricyclic heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318412-A1 Tricyclic heterocyclic compound and use thereof HTR2C, HTR2A, HTR5A USP30 4369/4885HDAC6 745/4885HDAC1 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.